{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-020482","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.616986+00:00","generated_at":"2026-05-15T23:37:12.169869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Natera Q4 2025 revenue $665.5M (+39.8% YoY); guides FY26 revenue $2.62-2.70B","bullets":["Revenue $665.5M Q4 2025 vs $476.1M Q4 2024 (+39.8%); FY2025 revenue $2,306.1M (+35.9%).","Gross margin 66.9% Q4 2025 vs 62.9% Q4 2024; FY2025 gross margin 64.7%.","Oncology test volumes up 54.7% YoY in Q4 (233,300 tests) and 51.6% for FY2025.","Full-year positive cash inflow of $107.6M; net loss $208.2M ($1.52 per diluted share).","FY2026 guidance: revenue $2.62-2.70B, gross margin ~63-65%, positive cash inflow."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-020482","json":"https://secwatch.observer/filing/0001104659-26-020482.json","markdown":"https://secwatch.observer/filing/0001104659-26-020482.md","text":"https://secwatch.observer/filing/0001104659-26-020482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465926020482/0001104659-26-020482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465926020482/tm266979d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:37:12.169869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}